Objective-Rupture of abdominal aortic aneurysms causes a high morbidity and mortality in the elderly population. Plateletrich thrombi form on the surface of aneurysms and may contribute to disease progression. In this study, we used a pharmacological approach to examine a role of platelets in established aneurysms induced by angiotensin II infusion into hypercholesterolemic mice. Approach and Results-Administration of the platelet inhibitors aspirin or clopidogrel bisulfate to established abdominal aortic aneurysms dramatically reduced rupture. These platelet inhibitors reduced abdominal aortic platelet and macrophage recruitment resulting in decreased active matrix metalloproteinase-2 and matrix metalloproteinase-9. Platelet inhibitors also resulted in reduced plasma concentrations of platelet factor 4, cytokines, and components of the plasminogen activation system in mice. To determine the validity of these findings in human subjects, a cohort of aneurysm patients were retrospectively analyzed using developed and validated algorithms in the electronic medical record database at Vanderbilt University. Similar to mice, administration of aspirin or P2Y 12 inhibitors was associated with reduced death among patients with abdominal aortic aneurysm. Conclusions-These results suggest that platelets contribute to abdominal aortic aneurysm progression and rupture.
A bdominal aortic aneurysms (AAA) affect 5% to 10% of the male and 1% of the female population over the age of 65 and is the 13th leading cause of death (estimated from 15 000 to 30 000 people, both primary and contributing) in the United States. 1, 2 AAA is defined as a permanent localized dilation in the arterial wall with a diameter >50% of normal. 3 It is an inflammatory disease that is often associated with formation of an intramural clot. Rupture of AAA frequently causes death. 4 In spite of a high incidence and catastrophic consequences, there is limited information about the sequence of events that lead to initiation, progression, and the eventual rupture of AAAs. Currently, the only treatment for AAA is surgical intervention after the aneurysm has reached a diameter of >5.5 cm. 5, 6 Because AAA is categorized as a peripheral artery disease, it is currently recommended that patients with AAA start a regiment of low-dose aspirin (ASA) therapy. 7, 8 
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Infusion of angiotensin II (AngII) into hypercholesterolemic mice induces formation of AAA localized to the suprarenal aorta. 9, 10 This model is highly reproducible and has been used to define mechanisms of vascular pathology associated with AAA. [11] [12] [13] AngII infusion promotes elastin fiber destruction, proteolytic destruction of medial connective tissue, inflammation, atherosclerosis within the aneurysm, and rupture, which are all features that occur in human AAA. 4, 14 Other mouse models of chemically induced AAA have been developed that include exposure of the aorta to elastase 15 or calcium chloride. 16 In addition, there is a xenograft rat model of AAA, which results in aortic dilatation and the presence of a mural thrombus in ≈20% of rats. 17 However, AngII infusion is the only consistent mouse model of aortic dilatation and rupture. 3, 4, 18 Platelets are required for hemostasis but also contribute to thrombosis and inflammation. 19 Primary hemostasis results from platelet adherence to selected adhesive glycoproteins in subendothelial matrix. Platelet activation, spreading, degranulation, and aggregation lead to formation of a platelet-rich hemostatic plug. 20 Platelet activation occurs through stimulation of a variety of G protein-coupled receptors with soluble agonists, such as thrombin, ADP, and thromboxane A 2 . 21 Activation of coagulation and production of thrombin activate platelets by cleavage of protease-activated receptors. Activated platelets release ADP and thromboxane A 2 that are required for sustained platelet activation and accumulation in a thrombus. 21 ADP stimulates the ADP receptors P2Y 1 and P2Y 12 , whereas thromboxane A 2 activates the thromboxane receptor. 21 The uncontrolled growth of a platelet-rich thrombus can occlude the blood vessel and result in myocardial infarction and stroke. Patients at risk for thrombosis are treated with platelet inhibitors, such as ASA, which blocks TXA (thromboxane A2) generation, and clopidogrel bisulfate, which inhibits P2Y 12 activation. In addition, the protease-activated receptor 1 inhibitor, Vorapaxar, has recently been approved for treatment of patients with cardiovascular disease. 22, 23 Studies in rat and mouse models demonstrate that platelet inhibitors reduce abdominal diameter (dilatation) and incidence of experimental aneurysm, suggesting that platelets may enhance AAA. [24] [25] [26] have an activated coagulation system and levels of thrombin generation correlate with the maximum diameter of the aorta in the patients. [27] [28] [29] [30] [31] [32] Importantly, platelets and platelet-specific secretions (soluble P-selectin, soluble CD40L, soluble glycoprotein V, and platelet-derived microparticles) are present in plasma of AAA patients and are specifically released from the luminal thrombus of an aneurysm. 25 Despite these results, several meta-analyses and retrospective clinical trials reported no significant benefit of platelet inhibitors on aneurysm growth and incidence of rupture. [33] [34] [35] In this study, we investigated the effects of pharmacological inhibition of platelet activation on aneurysms that were established by infusion of AngII. In addition, we evaluated the progression and rupture of AAA in patients with or without ASA or platelet inhibitors.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Effect of Platelet Inhibition on Established AAAs
Most patients are treated with ASA after being diagnosed with an AAA. 7, 8 To determine the effect of platelet inhibition on established AAAs, we generated AAAs in mice and then administered ASA or clopidogrel bisulfate. Ldlr −/− mice were fed a high-fat diet for 1 week before, and throughout AngII infusion for 28 days. Abdominal aortic diameters were measured by in vivo ultrasound and then mice were implanted with an additional 42-day AngII pump ( Figure 1A and 1D ). Mice were divided into 4 groups: placebo versus ASA and placebo versus clopidogrel bisulfate. ASA significantly reduced aracadonic acid-mediated integrin activation (data not shown) and completely suppressed plasma thromboxane B 2 ( Figure Supplement). We observed a decrease in abdominal aortic diameters with clopidogrel bisulfate or ASA versus placebo controls, but this was not significant ( Figure 1A , 1B, 1D, and 1E). Similarly, mice treated with ASA or clopidogrel bisulfate had a nonsignificant reduction in aortic arch area and diameter of the thoracic aorta (data not shown). Importantly, both platelet inhibitors protected mice with established AAA from rupture-induced death versus placebo controls ( Figure 1C and 1F; ASA 0% versus placebo 50%; clopidogrel bisulfate 0% versus placebo 47%; P<0.01). Furthermore, all deaths were because of rupture of the suprarenal abdominal region of the aorta. Interestingly, both platelet inhibitors also reduced the visible thrombi in mice with aortic arch or thoracic aneurysms (data not shown; P<0.048).
Platelet Inhibitors Decreased Platelet and Macrophage Accumulation and Matrix Metalloproteinase-2 and -9 Activity in Abdominal Aortas
Matrix metalloproteinase (MMP)-2 and MMP-9 have been shown to contribute to the initiation and progression of AAAs. 15, 16, 36 Macrophages are a primary source of MMP-9 and platelets contain both MMP-2 and MMP-9. [37] [38] [39] Notably, we found that platelet and macrophage accumulation was decreased significantly in mice treated with platelet inhibitors versus placebo controls (Figure 2A and 2C ). Therefore, we examined whether platelet inhibitors reduced levels of MMP activity in the aorta. Importantly, MMP activity in the aorta was significantly decreased with platelet inhibitors ( Figure 2B and 2C).
To further characterize the effect of platelet inhibitors on MMP activity in the aorta, abdominal aortas were removed and levels of pro and active MMP-2 and MMP-9 were quantified by ELISA and visualized with gelatin zymography. Platelet inhibitors significantly decreased levels of active MMP-2 and MMP-9 versus placebo controls ( Figure 3A-3D ). Interestingly, platelet inhibitors also decreased abdominal aortic tissue concentrations of total MMP-2, with a nonsignificant decrease in total MMP-9, as measured by ELISA ( Figure 3A and 3B). Importantly, the decrease in both MMP-2 and MMP-9 were significantly correlated with decreased macrophage (r 2 =0.835) and platelet (r 2 =0.913) counts in the AAAs of ASA or clopidogrel-treated mice (data not shown; P<0.001 for all correlations).
Platelet Inhibition Decreased Plasminogen Activators and Plasma Cytokines in AngII-Infused Mice
Plasmin generation by the plasminogen activators, urokinase plasminogen activator (uPA), and tissue-type plasminogen activator (tPA) is associated with increased levels of active MMP-2 and MMP-9. 40 We determined that total and active uPA and tPA in both plasma and abdominal aorta were significantly decreased by platelet inhibitors (Figure 4C-4F ). Furthermore, the endogenous inhibitor of uPA and tPA, plasminogen activator inhibitor 1, was significantly increased by platelet inhibitors (Figure 4A and 4B) . Platelets contain and secrete a variety of inflammatory and thrombotic molecules upon activation. 41 We ascertained if antiplatelet therapy decreased secretion and circulation of these molecules. Circulating and abdominal aortic platelet factor 4 was significantly decreased by antiplatelet therapy (Figure 5A ). In addition, antiplatelet therapy significantly attenuated several cytokines that are expressed by platelets, such as granulocyte colony stimulating factor, interferon-γ, regulated on activation normal T cell expressed and secreted (RANTES), interleukin-1α and β (IL-1α, β; Figure 5B -5F). Several other plasma inflammatory cytokines were also significantly decreased by antiplatelet therapy, including: IL-4, IL-5, IL-6, IL-7, IL-12(p70), IL-13, IL-17, KC, MCP-1 (monocyte chemoattractant protein 1), MIP-1α (macrophage inflammatory protein) and β, MIP-2, and tumor necrosis factor-α (data not shown). Importantly, the decreased level of abdominal aortic chemokines, cytokines, and plasminogen activators were all significantly correlated with decreased macrophage and platelet counts in the AAAs of ASA or clopidogrel-treated mice (data not shown; P<0.05).
Treatment With P2Y 12 Inhibitors and ASA Significantly Reduce Rupture and Dissection in Aneurysm Patients
A total of 1578 eligible patients (nonmissing data for all covariates) with aortic aneurysms (AAs; defined as either thoracic, abdominal, or thoracoabdominal) were identified totaling 5592 years of person time with an average follow-up of 2.28 years per individual. In total, 351 AA dissections (227) or ruptures (124) were recorded. Summaries of drug categories, demographic, and vital characteristics are presented in Table 1 .
After a diagnosis of AAs, P2Y 12 inhibitors (hazard ratio, 0.49; 95% confidence interval, 0.32-0.74; P =0.001) were significantly associated with decreased dissection or rupture after adjustment for vital (blood pressure and body mass index), demographic (age, sex, and race), and comorbid factors (diabetes mellitus, atrial fibrillation, heart failure, and chronic kidney disease; Table 1 ). This effect seems to be modified by whether the location of the aneurysm is thoracic versus abdominal, and the effect estimate in thoracic aneurysms is less protective and not statistically significant. ASA also protected against dissection or rupture (hazard ratio, 0.50; 95% confidence interval, 0.35, 0.72; P=1×10 −4 ) in adjusted analyses in both the thoracic and abdominal aorta ( Table 2) . Kaplan-Meier plots of survival for each drug exposure are presented in Figure 6A and 6B. Participants with at least 30 days of follow-up underwent sensitivity analyses, which did not substantively change event ratios (data not shown).
Discussion
A better understanding of the underlying pathophysiology in aneurysm disease is essential to develop nonsurgical therapeutics to reduce the burden of this condition in our aging population. A prominent feature of human AAAs is the accumulation of a laminated mural platelet-rich thrombus that develops along the luminal surface. 42, 43 Interestingly, a thrombus is a dynamic biological entity that is balanced between luminal renewal and abluminal fibrinolysis. 24, 25, 31, 44 Importantly, clinical studies suggest that thrombus volume or blood displacement caused by presence of mural thrombus may be a predictor of both AAA expansion and rupture. 43, 45 Therefore, it is surprising that the role of platelets in the formation of mural thrombi and their potential contribution to both the progression of AAAs has not been investigated systematically in a mouse model. We found that inhibition of platelets reduced rupture of established AAAs. Furthermore, we found ASA or P2Y 12 inhibitors administration may protect human AAA patients from rupture. In summary, our results suggest that inhibiting platelet activation slows AAA progression and reduces AAA rupture, which may support the clinical use of ASA and P2Y 12 inhibitors in AAA patients. ASA therapy is recommended for patients with AAA from the time of diagnosis until the perioperative period. 7, 8 It is currently hypothesized that the benefit of ASA in reducing cardiovascular morbidity and mortality and potentially AAA progression outweigh the risks of bleeding and AAA rupture. 7, 8 However, clinical studies examining the effects of platelet inhibitors (clopidogrel bisulfate and ASA) on nongenetically categorized AAA ruptures are extremely limited. Among a large meta-analysis of 6 studies, only 1 reported data with regard to AAA rupture. 34 The UKSAT (United Kingdom Small Aneurysm Trial) study reported that antiplatelet administration resulted in a rupture rate hazard ratio of 0.83, which was not significant. 34, 46 The mechanism by which ASA reduces aneurysm expansion is hypothesized to be via a decrease in thrombus formation, a reduction in aortic wall inflammation, and stabilization of the aortic wall. 47 A small retrospective study reported patients with medium-sized AAAs had significantly reduced AAA expansion and time to aneurysm repair on low-dose ASA. 47 Other studies have demonstrated a reduction in progression of small AAAs, although a definitive association between platelet inhibitors and aneurysm reduction was not established. 35 However, a large meta-analysis demonstrated that antiplatelet therapy resulted in a nonsignificant decrease in AAA growth compared with untreated aneurysm patients (P=0.241) after adjusting for confounding variables. 34 In our study, we observed protective associations between platelet inhibitors and AA rupture or dissection in 351 patients. We also found an inverse relationship between adverse AA events and non-ASA platelet inhibitor use, as well as an independent effect of ASA use. This finding indicates that addition of ASA or P2Y 12 inhibitors to standard therapy may be beneficial to AAA patients in addition to effects on other presumed cardiovascular diseases. In support of our findings, a phase 2 clinical trial is examining the efficacy of ticagrelor on patients with small AAAs (government clinical trial identifier: NCT02070653).
To better mimic this clinical situation, we administered platelet inhibitors to mice with established AAAs. We found that prolonged AngII infusion increased rate of aortic rupture, which was significantly reduced with clopidogrel bisulfate or ASA. These inhibitors also had no effect on abdominal aortic diameter (clopidogrel bisulfate, P=0.19 and ASA, P=0.08). Other studies have shown that a GP IIa/IIIb platelet inhibitor (abciximab) and a P2Y12 receptor antagonist (AZD6140) prevented aneurysm growth in the rat xenograft model of aneurysm. 17, 24, 25 While this model does not exhibit rupture, it does exhibit an intraluminal thrombus similar to human aneurysms in a certain percentage of rats. 17 We speculate that our results may be different because of the large amount of ruptures in our placebo groups, resulting in a lack of subsequent measurements of aortic diameters. Alternatively, a previous publication demonstrated a distinct difference between the incidence or maximal diameter of AngIIinduced AAAs and increased mortality because of rupture. 48 The continued accumulation of platelets and macrophages may result in proteolytic destruction of the aortic architecture via release of MMPs. Platelets 37, 38 and macrophages 39 are a robust source of MMPs. Furthermore, platelet-derived chemokines can regulate the expression of MMPs from VSMCs and macrophages. 49, 50 In addition, plasmin production by uPA or tPA is a critical step in fibrinolysis and MMP activation. 40 Here, we demonstrate that clopidogrel bisulfate and ASA intervention reduce platelet and macrophage infiltration into the vessel wall, circulating platelet-derived cytokines, plasminogen activators, and ultimately the amount of active MMP-2 and MMP-9 in the abdominal aortas. Importantly, MMP-2 and MMP-9 are correlated with increased aneurysmal disease and rupture. 16, 51 Furthermore, several attenuated cytokines and chemokines play a significant role in AAA progression. [52] [53] [54] [55] In addition, there is a role for the uPA, uPAR, tPA, and plasminogen activator inhibitor 1 plasminogen axis in both the progression and the rupture of experimental aneurysm. 48, [56] [57] [58] Although it is uncertain whether these MMPs, cytokines, and plasminogen activators/inhibitors are primarily derived from platelets or macrophages, there are significant correlations between platelets and macrophages among all of these inflammatory mediators. However, there are several contradictions in the literature about the role of Th1/Th2 chemokines and cytokines and MMPs with regard to the outcome of AAA pathogenesis. 59, 60 Indeed, the differences in cytokine and MMP profile only reflect a single stage of AAA development/degeneration, thus complicating a proper analyses and interpretation of these correlations.
In conclusion, we show that platelet accumulation and activation is detrimental in a mouse model of established AAAs.
The pathological role seems to involve macrophage recruitment and the production of MMPs resulting in vessel instability and rupture. We further show a positive association with platelet inhibitors and ASA in the prevention of human AA rupture or dissection. The results indicate that platelet inhibitors are beneficial in pre-existing aneurysms. Future studies will be directed at dissecting the role of platelet signaling in AAAs. 
